申请人:SANTEN PHARMACEUTICAL CO., LTD.
公开号:EP0979817A1
公开(公告)日:2000-02-16
The present invention relates to leukotriene A4 hydrolase inhibitors containing compounds represented by the formula [I] or salts thereof as active ingredients,
wherein R1 represents hydrogen, alkyl, phenylalkyl, alkanoyl or benzoyl; R2 and R3 each represent hydrogen or alkyl; R4 represents hydroxyl, alkoxy, phenylalkoxy, amino, alkylamino or phenylalkylamino; R5 represents phenylalkyl or naphthylalkyl; "Z" represents sulfur or oxygen; "A" represents alkylene; and "n" represents 0, 1 or 2; provided that the phenyl ring in R1 can be substituted by alkyl, alkoxy or halogen, and that the phenyl ring or the naphthyl ring in R5 can be substituted by alkyl, cycloalkyl, alkoxy, alkylthio or halogen.
本发明涉及含有式[I]代表的化合物或其盐作为活性成分的白三烯 A4水解酶抑制剂、
其中 R1 代表氢、烷基、苯基烷基、烷酰基或苯甲酰基;R2 和 R3 各自代表氢或烷基;R4 代表羟基、烷氧基、苯基烷氧基、氨基、烷基氨基或苯基烷基氨基;R5 代表苯基烷基或萘基烷基;"Z "代表硫或氧;A "代表亚烷基;"n "代表 0、1 或 2;但 R1 中的苯基环可被烷基、烷氧基或卤素取代,R5 中的苯基环或萘基环可被烷基、环烷基、烷氧基、烷硫基或卤素取代。